Understanding FDA 510(k) Clearance: What NeuroICH K241719 Means for Patient Safety

Why FDA Clearance Is the Threshold for Clinical AI

The AI diagnostics market is crowded with claims. Vendors promise dramatic accuracy. Marketing materials cite impressive statistics. But in healthcare, where a missed diagnosis can mean permanent disability or death, claims are not enough.

The U.S. Food and Drug Administration's 510(k) clearance process exists to create a validated threshold between marketing claims and clinical deployment. When an AI medical device receives 510(k) clearance, it has undergone rigorous independent review of its design, performance data, clinical evidence, and manufacturing controls. The cleared device is legally permitted to be marketed and used in clinical settings as a medical device.

SaveLife.AI's NeuroICH™ received FDA 510(k) Clearance on November 7, 2024, with clearance number K241719. This is what it means, and why it matters.

What Is the 510(k) Pathway?

The 510(k) pathway is the FDA's premarket notification process for medical devices, including Software as a Medical Device (SaMD). To receive clearance, the manufacturer must demonstrate that the new device is "substantially equivalent" to a legally marketed predicate device in terms of intended use and technological characteristics.

For AI diagnostic tools, this is not a rubber stamp. The process requires:

• Clinical performance data, rigorous sensitivity and specificity testing across diverse patient populations
• Algorithm documentation, detailed disclosure of model architecture, training data, and validation methodology
• Cybersecurity plan, Software Bill of Materials (SBOM), vulnerability management, and patch cadence
• Labeling and indications for use, precise clinical context statements that govern how the device may be used
• Quality management system, design controls compliant with 21 CFR Part 820

For AI tools specifically, the FDA has increasingly required multi-reader studies, real-world performance commitments, and post-market surveillance plans as part of its Total Product Life Cycle (TPLC) framework.

NeuroICH: The Clinical Problem It Solves

Intracranial hemorrhage (ICH) is a medical emergency. When blood accumulates inside the skull, whether from ruptured blood vessels (intracerebral hemorrhage), burst aneurysms (subarachnoid hemorrhage), or trauma (subdural and epidural hematoma), the consequences are immediate and devastating.

The numbers frame the urgency:

• Only 33% of stroke patients receive treatment within the golden hour
• Over 79% of stroke survivors face long-term disabilities
• Every 60 minutes without treatment: 120 million neurons degenerate, 714 km of neural fibers are lost
• Every minute of delay costs 1.9 million neurons, 10% worse outcomes, and $1.4 million in lifetime care costs

The bottleneck is not clinical knowledge. It is detection speed. A non-contrast head CT may sit in a radiologist's worklist for minutes or hours before review. NeuroICH eliminates that wait.

NeuroICH Performance: What K241719 Validated

FDA clearance K241719 reflects the following clinically validated performance metrics for NeuroICH™:

These metrics were validated across multiple patient populations, age groups, genders, and CT scanner manufacturers including Siemens and Philips, and across various slice thicknesses. This multi-vendor, multi-protocol validation is a requirement for clinical-grade performance claims and is what distinguishes FDA-cleared performance data from internal benchmarks.

The hemorrhage types NeuroICH detects span the full ICH spectrum:

• IPH, Intracerebral/intraparenchymal hemorrhage
• IVH, Intraventricular hemorrhage
• SAH, Subarachnoid hemorrhage
• SDH, Subdural hematoma
• EDH, Epidural hematoma

From Detection to Outcome: The Clinical Chain

What makes NeuroICH's clearance clinically significant is not just detection accuracy, it is what detection speed enables downstream.

When a CT scan arrives at a facility, NeuroICH analyzes it within 60 seconds and delivers a mobile alert to the treating physician within 30 seconds. This triggers the clinical response chain that determines patient outcomes.

The operational impact is measurable:

Financially, early ICH detection reduces average treatment cost from $85,000 (delayed detection) to $35,000 (early detection), a $50,000 cost avoidance per patient and an $8 return on every $1 invested in the technology.

What FDA Clearance Means for Your Organization

Healthcare organizations deploying AI diagnostics face real liability questions. An AI tool that is not FDA cleared may be powerful, but it occupies a legally ambiguous space in the clinical workflow. Hospitals and health systems must consider:

• Can this tool be listed as part of the standard of care?
• Does using this tool create or reduce malpractice exposure?
• Will payers recognize reports enhanced by this tool?
• Will your clinical staff trust outputs from a non-validated system?

FDA 510(k) Clearance answers these questions. NeuroICH K241719 is a cleared medical device. It can be legally marketed and clinically deployed as a diagnostic support tool. Its performance claims are FDA-validated, not self-reported.

NeuroICH Is Free for LMICs

SaveLife.AI has made NeuroICH™ available free of charge for all low and middle-income countries (LMICs). Intracranial hemorrhage is a global emergency. Stroke outcomes in LMICs are disproportionately worse because of diagnostic delays, limited radiologist availability, and infrastructure gaps.

FDA-cleared AI should not be a technology only available to wealthy health systems. Making NeuroICH free for LMICs reflects SaveLife.AI's founding principle, rooted in the belief that saving one life is as if saving all of humanity.

The Regulatory Infrastructure Behind Clearance

NeuroICH's FDA clearance is supported by SaveLife.AI's comprehensive regulatory framework:

• Design Controls, full SaMD documentation pathways
• Cybersecurity, SBOM management, coordinated vulnerability disclosure, patch cadence
• Post-Market Surveillance, real-world performance monitoring and complaint handling
• 21 CFR Part 11 Compliance, full audit trails for all AI outputs
• HITRUST CSF Certified and HIPAA Compliant, healthcare-specific security and privacy standards

This infrastructure ensures that clearance is not a one-time event but an ongoing commitment to validated, monitored clinical performance.

Ready to see NeuroICH and the AI-Suite in action? Book a demo with SaveLife.AI.